On the Record · BeOne Medicines

BeOne Medicines acquisitions, on the record

The businesses BeOne Medicines bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
Ensem Therapeutics, Inc.'s oral cyclin-dependent kinase 2 (CDK2) inhibitor Word for word“On November 21, 2023, we announced an agreement to acquire an exclusive global license to Ensem Therapeutics, Inc.'s ("Ensem") Investigational New Drug ("IND") application-ready oral cyclin-dependent kinase 2 ("CDK2") inhibitor.” 10-K for 2023	agreed acquisition	November 21, 2023	—
Celgene's commercial operations in China Word for word“In 2017, we acquired Celgene's commercial operations in China and an exclusive license to Celgene's (now BMS's) commercial cancer portfolio in China, REVLIMID, VIDAZA and ABRAXANE.” 10-K for 2023	acquisition	2017	—
Pi Health business Word for word“In the first quarter of 2024, the Company divested the net assets comprising substantially all of its Pi Health business with a carrying value of $ 38,063 .” 10-K for 2024	divestiture	In the first quarter of 2024	—

Deal filings since 2016

2025-11-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-08-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-12-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-08-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-01-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-12-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-12-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-01-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-12-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-09-24 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-07-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-03-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-12-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-10-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-08-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-08-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-07-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-01-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-08-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-07-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-04-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-03-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-11-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-04-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-02-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement

Read from BeOne Medicines’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.